40685-78-7

Basic information

• Product Name: 4-UREIDO-BENZENESULFONYL CHLORIDE
• Synonyms: 4-UREIDO-BENZENESULFONYL CHLORIDE
• CAS NO: 40685-78-7
• Molecular Formula: C₇H₇ClN₂O₃S
• Molecular Weight: 234.66
• Mol File: 40685-78-7.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-UREIDO-BENZENESULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-UREIDO-BENZENESULFONYL CHLORIDE(40685-78-7)
• EPA Substance Registry System: 4-UREIDO-BENZENESULFONYL CHLORIDE(40685-78-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22-43
• Safety Statements: 36/37
• Hazardous Substances Data: 40685-78-7(Hazardous Substances Data)

Upstream product

• 64-10-8 phenyl carbamate 

Downstream Products

• 5657-41-0 N³-(4-sulfamoylphenyl)urea 
• 17101-20-1 N-carbamoyl-sulfanilic acid anilide 
• 515-59-3 sulfamethylthiazole 
• 547-52-4 4-amino-N-[4-(aminosulfonyl)phenyl]-benzenesulfonamide 
• 849349-13-9 4-[(aminocarbonyl)amino]-N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-methylbenzenesulfonamide 
• 259182-97-3 N-(4-{[2-({[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl}sulfinyl)benzimidazol-1-yl]sulfonyl}phenyl)urea 
• 259182-96-2 N-[4-[[6-methoxy-2-[[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl]sulfinyl]benzimidazol-1-yl]sulfonyl]phenyl]urea 
• 259182-95-1 N-[4-[[5-methoxy-2-[[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl]sulfinyl]benzimidazol-1-yl]sulfonyl]phenyl]urea 
• 259183-25-0 N-(4-{[2-({[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl}sulfinyl)benzimidazol-1-yl]sulfonyl}phenyl)urea 
• 1222558-90-8 C₂₆H₃₅N₅O₃S 

Relevant articles and documents

Prodrugs of proton pump inhibitors

Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under physiological conditions to provide the proton pump inhibitors with a half life measurable in hours, and are capable of providing sustained plasma concentrations of the proton pump inhibitor drugs for longer time than presently used drugs. The generation of the proton pump inhibitor drugs from the prodrugs of the invention under physiological conditions allows for more effective treatment of several diseases and conditions caused by gastric acid secretion.